Published in J Mol Med (Berl) on January 29, 2010
Human mitochondrial DNA: roles of inherited and somatic mutations. Nat Rev Genet (2012) 2.59
Inherited mitochondrial DNA variants can affect complement, inflammation and apoptosis pathways: insights into mitochondrial-nuclear interactions. Hum Mol Genet (2014) 1.23
Molecular and bioenergetic differences between cells with African versus European inherited mitochondrial DNA haplogroups: implications for population susceptibility to diseases. Biochim Biophys Acta (2013) 1.10
Association between mitochondrial DNA variations and Alzheimer's disease in the ADNI cohort. Neurobiol Aging (2010) 1.05
Mitochondrial DNA variants mediate energy production and expression levels for CFH, C3 and EFEMP1 genes: implications for age-related macular degeneration. PLoS One (2013) 0.96
Functional differences between mitochondrial haplogroup T and haplogroup H in HEK293 cybrid cells. PLoS One (2012) 0.95
Meclizine is neuroprotective in models of Huntington's disease. Hum Mol Genet (2010) 0.92
NMDA receptor gene variations as modifiers in Huntington disease: a replication study. PLoS Curr (2011) 0.87
May "mitochondrial eve" and mitochondrial haplogroups play a role in neurodegeneration and Alzheimer's disease? Int J Alzheimers Dis (2011) 0.83
The emergence of the mitochondrial genome as a partial regulator of nuclear function is providing new insights into the genetic mechanisms underlying age-related complex disease. Hum Genet (2013) 0.83
Huntingtin protein is essential for mitochondrial metabolism, bioenergetics and structure in murine embryonic stem cells. Dev Biol (2014) 0.80
Mitochondrial Biology and Neurological Diseases. Curr Neuropharmacol (2016) 0.79
Mitochondrial DNA polymorphisms/haplogroups in hereditary spastic paraplegia. J Neurol (2011) 0.77
Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease. Mol Neurodegener (2014) 0.77
Relationship between European mitochondrial haplogroups and chronic renal allograft rejection in patients with kidney transplant. Int J Med Sci (2014) 0.75
Wheels within wheels: multifocal autoimmune myelitis in a woman with Huntington's disease. J Neurol (2012) 0.75
Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med (2012) 6.93
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet (2008) 3.68
Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity (2008) 3.67
Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol (2005) 3.42
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain (2011) 3.38
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med (2012) 2.90
New glucocorticoids on the horizon: repress, don't activate! J Rheumatol (2005) 2.70
Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood (2011) 2.44
Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry (2013) 2.23
Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet (2005) 2.20
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Diagnosis and management of calcified carotid artery atheroma: dental perspectives. Oral Surg Oral Med Oral Pathol Oral Radiol (2012) 2.14
Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol (2004) 2.11
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology (2013) 2.02
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig (2010) 1.91
CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med (2002) 1.91
PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J Immunol (2009) 1.79
Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med (2005) 1.79
Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology (2012) 1.78
Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford) (2011) 1.74
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry (2012) 1.66
Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med (2009) 1.63
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2011) 1.62
Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci U S A (2009) 1.56
Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol (2002) 1.53
Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain (2010) 1.52
Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol (2007) 1.52
The IBV Valve trial: a multicenter, randomized, double-blind trial of endobronchial therapy for severe emphysema. J Bronchology Interv Pulmonol (2014) 1.51
The Asthma-COPD Overlap Syndrome: A Common Clinical Problem in the Elderly. J Allergy (Cairo) (2011) 1.49
Faster perceptual learning through excitotoxic neurodegeneration. Curr Biol (2012) 1.46
Towards individualised multiple-sclerosis therapy. Lancet Neurol (2005) 1.46
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler (2012) 1.46
Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS One (2009) 1.44
Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain (2007) 1.42
Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. J Neurol Neurosurg Psychiatry (2012) 1.41
Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord (2005) 1.33
Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler (2011) 1.33
NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics (2004) 1.31
Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol (2013) 1.30
New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum Genet (2004) 1.29
Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit Rev Immunol (2009) 1.27
Intra- and internerve cross-sectional area variability: new ultrasound measures. Muscle Nerve (2012) 1.25
Relationship between major depression and heart rate variability. Clinical consequences and implications for antidepressive treatment. Psychiatry Res (2002) 1.25
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler (2013) 1.22
PGC-1alpha as modifier of onset age in Huntington disease. Mol Neurodegener (2009) 1.22
Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol (2008) 1.22
Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol (2005) 1.20
Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol Dis (2008) 1.20
Positional mapping for amplified DNA sequences on 1q21-q22 in hepatocellular carcinoma indicates candidate genes over-expression. J Hepatol (2003) 1.17
Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain (2006) 1.17
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol (2013) 1.17
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol (2011) 1.17
Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. Eur Heart J (2010) 1.14
NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet (2007) 1.13
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain (2003) 1.11
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol (2012) 1.11
Assessment of simple movements reflects impairment in Huntington's disease. Mov Disord (2006) 1.11
Assessment of complex movements reflects dysfunction in Huntington's disease. J Neurol (2003) 1.10
Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One (2011) 1.10
Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve (2004) 1.09
Naive CD8 T-cells initiate spontaneous autoimmunity to a sequestered model antigen of the central nervous system. Brain (2008) 1.08
Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. Ann Neurol (2012) 1.07
Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain (2012) 1.06
The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington's disease. Neurogenetics (2005) 1.06
Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol (2007) 1.05
Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler (2011) 1.05
Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Ther Adv Neurol Disord (2011) 1.05
Therapies for multiple sclerosis: translational achievements and outstanding needs. Trends Mol Med (2013) 1.04
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler (2011) 1.03
The role of the immune system in Huntington's disease. Clin Dev Immunol (2013) 1.03
Short-term effects of intravenous benzodiazepines on autonomic neurocardiac regulation in humans: a comparison between midazolam, diazepam, and lorazepam. Crit Care Med (2002) 1.03
Analysis of maturation states of rat bone marrow-derived dendritic cells using an improved culture technique. Histochem Cell Biol (2002) 1.02
Astrocytes are less efficient in the removal of apoptotic lymphocytes than microglia cells: implications for the role of glial cells in the inflamed central nervous system. J Neuropathol Exp Neurol (2002) 1.02
Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann Neurol (2011) 1.02
Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int J Mol Sci (2012) 1.02
Progressive multifocal leukoencephalopathy and natalizumab. J Neurol (2011) 1.01
What is influencing the phenotype of the common homozygous polymerase-γ mutation p.Ala467Thr? Brain (2012) 1.01
Response inhibition subprocesses and dopaminergic pathways: basal ganglia disease effects. Neuropsychologia (2009) 1.01
Hereditary motor and sensory neuropathy caused by a novel mutation in LITAF. Neuromuscul Disord (2009) 1.01
Complex genetic predisposition in adult and juvenile rheumatoid arthritis. BMC Genet (2004) 1.01